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Objectives: Tobacco smoking-related diseases continue to be of great health concern
for the public, in general, and may be particularly deleterious for immunosuppressed
HIV-positive individuals, who exhibit widespread tobacco use.
Methods: A total of 521 HIV-infected subjects consecutively admitted to Jackson
Memorial Hospital between 2001—2002 were enrolled in the study. Research data
included a medical history, details of tobacco and illicit drug use and complete
computerized hospital information. Blood was drawn to obtain T lymphocyte profiles
and viral load levels. Statistical analysis methods included Pearson, Student’s t- and
Chi-square tests and SAS Proc CATMOD.
Results: Tobacco use was prevalent, with 65% of the 521 HIV-positive hospitalized
patients being current smokers. Overall, current tobacco users reported smoking an
average of 15  13 cigarettes per day for an average of 15  14 years, with 40%
smoking more than one pack per day. Pulmonary infections accounted for 49% of the
total hospital admissions: 52% bacterial pneumonias, 24% Pneumocystis carinii pneu-
monia (PCP), 12% non-tuberculous mycobacterial diseases (NTM), 11% tuberculosis
and 1% bronchitis. Many of the respiratory patients (46%) had been on highly active
antiretroviral therapy (HAART) for over six months and 42% had received PCP and/or* Corresponding author. Tel.: +1 305 243 4072; fax: +1 305 243 4687.
E-mail address: mmiguez@med.miami.edu (M.J. Miguez-Burbano).
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NTM prophylaxis. After matching the cases by HAART and CDC stage, the hazardous
risk of being hospitalized with a respiratory infection was significantly higher for
smokers than non-smokers (95% CI 1.33—2.83; p = 0.003). Respiratory infections were
noted in (37%) of the HAART-treated patients, and most (67%) occurred in smokers.
CATMOD analyses controlling for HAART, viral load and CD4, indicated that HIV-
infected smokers were three times more likely to be hospitalized with PCP and twice
as likely to be hospitalized with community-acquired pneumonia than non-smokers,
with increased risk related to the number of cigarettes/day in a dose-dependent
manner.
Conclusions: Tobacco use, which is widespread among HIV-infected subjects,
increases the risk of pulmonary diseases, particularly PCP and CAP, two respiratory
infections with high prevalence and morbidity risks even in the era of HAART.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Background
Current information regarding tobacco use and HIV/
AIDS disease progression is limited and controver-
sial.1—4 Although cigarette smoking has been recog-
nized as a leading preventable cause of premature
death in the United States, some studies have indi-
cated that tobacco use does not impact HIV disease
progression, development of opportunistic infec-
tions, PCP or HIV-related mortality.5,6 Burns et al.4
documented only a slightly increased risk of oral
candidiasis (relative hazard, RH = 1.3) and pneumo-
nia (RH = 1.57) in HIV-positive smokers. Their study
also indicated that HIV-positive smokers were less
likely to develop Kaposi’s sarcoma, cytomegalovirus
disease, extrapulmonary cryptococcosis, aphthous
ulceration and molluscum contagiosum, than former
smokers or those who have never smoked.
Sustained interest in tobacco use is underscored
by studies revealing that infections of the lower
respiratory tract continue to be a primary cause
of morbidity in HIV-infected patients even during
the HAARTera.7,8 Respiratory disease is the result of
several factors that favor the entrance, establish-
ment andmultiplication of pathogenic organisms, as
well as factors that decrease respiratory defense
mechanisms in the host. Widely accepted risk fac-
tors for community-acquired pneumonia among the
general population include, for example, malnutri-
tion, aging, immunosuppression, and tobacco smok-
ing.9 Risk factors for developing a first episode of
bacterial pneumonia among HIV-positive intrave-
nous drug users between 1988 and 1992 included
CD4 cell count of<200  106/L, age between 30—40
years, and smoking drugs (but not cigarettes).2
Conley and colleagues9 found that although cigar-
ette smoking was not associated with clinical AIDS,
nor a decrease in CD4 cell count, smokers were at
three times the risk of community-acquired pneu-
monia, compared to non-smokers. In turn low CD4,high viral loads and oral candidiasis were the only
predictors of PCP.10—12 The present study was
designed to evaluate potential risk factors of
respiratory disease, particularly PCP, in relationship
to tobacco use, while controlling for drug use,
alcohol consumption and disease status in HIV-
infected men and women hospitalized at one of
the main HIV/AIDS study centers in the United
States.Methods and material
Study population
HIV-infected adult subjects (aged over 18 years)
consecutively admitted to the University of
Miami/Jackson Memorial Hospital, a central referral
hospital with state-of-the-art technology, were eli-
gible for enrollment in this case-control, cross-sec-
tional study during the period from September
2001—December 2002. Following admission, stable
patients were contacted and fully informed about
the study. Written informed consent and medical
releases were obtained from all participants. The
Human Studies Committee of the University of
Miami School of Medicine Institutional Review Board
approved the project.
Research data
An HIV-experienced medical doctor completed all
the enrollment procedures. The following data were
obtained from every patient: (1) demographic infor-
mation including, age, sex, race/ethnicity, years of
education, socio-economic strata and (2) HIV infec-
tion-related data including risk factors for HIV infec-
tion, CDC stage of disease and occurrence of
opportunistic infections. To investigate risk factors
associated with respiratory diseases in HIV-infected
210 M.J. Miguez-Burbano et al.subjects, the research questionnaires included a
complete past medical history, current HIV-related
treatments, and history of tobacco, alcohol and
illegal drug use.
Hospitalization
Computerized diagnostic code data included the
number of previous admissions to the hospital and
length of stay, date of present admission, and pre-
sumptive admission diagnosis. Once the patient was
discharged from the hospital, data coding incorpo-
rated the main discharge diagnosis, length of stay,
and a list of diagnostic exams and procedures.
Medical history
All study participants were questioned as to medical
history. AIDS-defining criteria, such as opportunistic
infections, were carefully documented and HIV dis-
ease status was established according to the Centers
for Disease Control (CDC) criteria using both clinical
information and immune parameters.
Once all research forms and visit procedures had
been completed, a medical chart review was con-
ductedby themedical study team(threeexperienced
HIV clinician/researchers and pneumologists), in
order to compare and validate the collected informa-
tion. All available clinical data, antiretroviral medi-
cations, antimicrobial treatment, laboratory results,
radiology studies (i.e. X-rays, scans) and response to
treatment were reviewed by this panel to confirm
both past and present disease diagnosis.
Immune assessment
Immune assessment included measurements of T
helper and suppressor lymphocytes and determina-
tion of viral load burden. Current (within one month
from day of admission) CD4 cell counts and viral load
were abstracted from medical records. If measure-
ments were unavailable, blood was drawn to deter-
mine current CD4 cell counts and viral load levels.
Flow cytometry was used to quantify the percen-
tage and absolute numbers of T lymphocyte sub-
populations. A four-color direct immunofluores-
cence procedure (Becton Dickinson, San Jose,
CA) was used to determine the percentages and
absolute counts of the helper inducer T cells
(CD3+/CD4+).
A reverse transcriptase polymerase chain reac-
tion was used to quantify HIV viral load in plasma
from EDTA-collected blood samples that were
separated and processed within 6 hours of collec-
tion. The test was performed using the Roche
reverse transcriptase polymerase chain reaction.The current version of this assay has a reportable
range of >200 to 750,000 RNA copies per millimeter
of plasma.
HAARTwas defined as the combination of therapy
with two nucleoside reverse transcriptase inhibitors
(NRTIs) and one non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) or two nucleoside analogues
and one protease inhibitor or three nucleosides
including abacavir or four or more drugs.
Cause of hospitalization
Medical chart review was performed to determine
the most accurate cause of hospitalization (i.e.
clinical diagnosis and infectious pathogen). Routine
clinical tests ordered by the physicians were avail-
able for review and included a complete blood
count, serum chemistry tests, urinalysis, expecto-
rated sputum Gram’s stain and culture, and blood
cultures. Additional clinical diagnostic tests,
ordered at the discretion of the treating physicians,
were included in the database.
Respiratory infection
A diagnosis of respiratory infection required a com-
bination of at least two of the following criteria: (1)
medical diagnosis; (2) X-ray findings; (3) positive
culture; (4) isolation/visualization of the organism
in sputum or bronchial wash and; (5) response to
treatment. A definitive diagnosis was established by
the isolation of the organism in blood, sputum or
bronchial wash and response to treatment.
A specific diagnosis of community-acquired pneu-
monia (CAP) was based on the Infectious Disease
Society of America13 criteria based on (1) history
and physical examination; (2) chest radiography; (3)
sputum Gram stain and culture and when necessary
bronchoscopy/biopsy (all accompanied by determi-
nation of complete blood and differential counts
and arterial blood gases when necessary); (4) cure
with antibacterial treatment.
Pneumocystis carinii pneumonia (PCP) was con-
sidered to have caused pneumonia when a patient
had respiratory symptoms and P. carinii was isolated
in sputum. A clinical diagnosis of PCP was presumed
if three or more of the following clinical criteria
were present: (1) clinical impression of dyspnea,
severe hypoxia (cyanosis or oxygen saturation<86%,
as measured by pulse oximetry); (2) a lactate dehy-
drogenase level of 1000 U/L; (3) thorax X-ray con-
firming the respiratory infection (radiology suggests
the image is compatible with diagnosis of PCP) at
admission and 48 hours thereafter; (4) response to
treatment (i.e. trimethoprim/sulfamethoxazole)
when presumptive diagnosis of PCP was established.
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established by isolation and culture of the causative
organism. A diagnosis of pulmonary infection due to
non-tuberculous Mycobacteria (NTM) was estab-
lished when the following criteria were satisfied:
(1) underlying conditions (immunosupression, beha-
viors and diseases); (2) clinical signs/symptoms,
radiographic studies (chest X-ray or CTscan abnorm-
alities) and bacteriological criteria (at least two
separate positive sputum cultures, or isolation in
a bronchial wash or tissue biopsy cultures).
Tobacco use questionnaire
Information on tobacco use was collected for cigar-
ettes, cigars, and pipes, including frequency of
tobacco use, recorded as number of cigarettes
per day (current). Past tobacco use was also
recorded as number of cigarettes smoked per day.
For those who reported past tobacco use, data were
recorded for the age when they began smoking and
stopped smoking. The number of years of tobacco
use was also recorded, and information confirmed
with medical records. Based on the above variables,
participants were classified as ‘non-smokers’ if they
reported never having smoked. An ever smoker was
defined as having had at some time smoked at least
one cigarette, cigar or pipe per week for at least
three months. An ex-smoker was an individual who
had stopped smoking for at least one year prior to
the interview. Current smokers were those who
reported regular tobacco use.
Drug and alcohol use questionnaire
The drug and alcohol use history questionnaire
included type of drug used, route of ingestion and
frequency of use. The frequency of drug and alcohol
use was graded on a numerical scale: 0 = never;
1 = once last 30 days; 2 = once/week; 3 = 3—4 times
per week; 4 = daily; 5 = more than once a day and
6 = past use. The duration of alcohol and drug use in
years, as well as the estimated amount per day was
also recorded.
Statistical analyses
The data were analyzed using SAS version 6.12 and
SPSS version 10. Following descriptive statistical
analyses, mean variables were compared using
Student’s t test and one-way ANOVA procedures.
Correlations between the main variables of inter-
est (i.e. CD4, viral load, number of cigarettes per
day) were examined with Pearson’s correlation
coefficient. For most analyses, participants were
divided according to hospital admission (respira-tory and non-respiratory). Since cigarette smoking
was correlated with other substance abuse, ana-
lyses of drug and disease events were conducted
and controlled for in the final analyses. To control
for the potential differential effect of smoking
across different CDC stages, data analyses were
stratified according to CD4 cell counts categorized
as <200, 201—500 and more than 500 CD4 cell
counts  106/L.
Additional analyses were performed using multi-
nominal regression and SAS Proc CATMOD (catego-
rical models) analysis to describe the associations
between discharge diagnosis and tobacco use while
controlling for risk factors, immune function (dif-
ferent T cells, HIV viral load), and antiretroviral
therapy. Alpha was set at 0.05.Results
Study population: sociodemographic
characteristics
Five hundred and twenty-one HIV-infected patients
(300 men, 221 women) were enrolled in the study
over a one-year period (2001—2002). Participants
ranged in age from 20—72 years old and the average
age of the study group was 42  9 years. More than
half (61%) of the participants self-identified as Afri-
can American, 17% were Hispanic, 18% Haitian and
4% were Caucasian. The study group varied in years
of education, which ranged from 1—18 years (mean
9  4 years) with 14% of the group having more than
12 years of formal education. Most participants
(89%) reported an annual household income of less
than $10,000, 8% reported between $11,000—
20,000 and 3% stated an income of more than
$20,000.
Current alcohol use was declared by 46% of the
study population with 17% stating daily alcohol use
(95% CI 14.0—20.5). Marijuana use was reported by
20% of the study population. Crack/cocaine use was
indicated by 48% of the patients; 19% used crack/
cocaine on a daily basis (95% CI 16—22.8). Only 2% of
the group reported heroin use.
Hospitalization admissions and discharge
diagnoses
Respiratory diseases accounted for 49% of the total
admissions (n = 255) followed by gastrointestinal
problems and hepato-pancreatic diseases (16%),
central nervous system (11%), and renal problems
(14%). Additional admission diagnoses were distrib-
uted among cardiovascular diseases (4%), sepsis
(3%), malignancy (5%) and traumas (1—2%). An
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condition.
PCP continued to be an important cause of
respiratory infection. This condition was diagnosed
in 24% (n = 65) of the HIV-infected patients. In 20% of
the study participants with respiratory infections
mycobacteria were cultured in sputum and/or blood
(Mycobacterium tuberculosis (n = 28)). Non-tuber-
culous mycobacterial disease was diagnosed in 30
patients: discharge diagnosis was confirmed by clin-
ical history and positive cultures. In a small propor-
tion (4%) of the respiratory cases, the discharge
diagnosis was bronchitis. Patterns of respiratory
infections were similar in both men and women.
HIV CDC classification, immune status and
HIV treatment
The patient sample indicated a broad range of years
living with HIV, ranging from six months up to 20
years; on average, the study population had been
living with the retroviral infection for 7  6 years.
The main route of transmission reported by partici-
pants was unprotected heterosexual contact (89%)
with 6% attributed to intravenous drug use and 5%
to unprotected homo/bisexual intercourse. The
mean CD4 count of the total group was 172  135
cells  106/L. One third of the group had >200
cells  106/L. According to CDC criteria, most of
the participants (80%) had AIDS (AIDS-defining con-
dition and/or <200 CD4 cells  106/L). The remain-
ing 20% had symptomatic HIV infection. No significant
differences in CD4 cell counts were observedTable 1 Study group characteristics.
Variables Smoke
Gender
Men (n = 300) 197












Years living with HIV (n = years) 8  6
CDC classification
HIV 17%
AIDS 83%between patients hospitalized with respiratory
infections (163  116 cells  106/L) and those hospi-
talized for other reasons (179  141 cells  106/L,
p = 0.2). Less than one third of the study participants
(29%) were using trimethoprim-sulfamethoxazole
and/or other prophylaxis.
The median viral load of the study group was
84599 HIV copies/ml with 20% of the patients having
undetectable viral load levels. A review of antire-
troviral therapy history revealed that 40% of the
study group was using antiretroviral therapies,
although more than half (60%) of this group was
not using HAART at the time of the interview. Most
participants in the study (85%) had previous antire-
troviral experience.
As expected, HAART-treated participants had sig-
nificantly higher CD4 cell counts (171  216  106/
L), than non-treated patients (115  154  106/L,
p = 0.001) and lower HIV viral loads (treated
81151  124212 vs. non-treated 314145  309164
HIV copies/ml p = 0.0001). Thirty-five percent of
those on HAART had achieved undetectable viral
loads at the time of hospitalization.
Lower respiratory infections by immune
status and antiretroviral treatment
As expected PCP was twice as common in patients
with CD4 lymphocyte counts <200 cells  106/L and
those with high viral loads (>150,000 RNA HIV,
p = 0.02).
Univariate analyses indicated that patients with
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ease than other respiratory infections (95% CI 1.07—
11.7, p = 0.02); this group was also twice as likely to
develop a non-tuberculous mycobacterial disease,
but not a tuberculous disease.
A significantly lower proportion of the respiratory
cases (36%) occurred in patients receiving HAARTas
compared to those not using antiretroviral treat-
ment (64%, p = 0.0001). Specifically, 70% of the PCP
( p = 0.005), 63% of the CAP ( p = 0.0004) and 54% of
the mycobacterial diseases occurred in patients who
were not using HAART at the time of admission. In
patients receiving HAART, a total of 98 respiratory
cases occurred, this corresponds to 19% of the total
admissions with more than one third (37%) of these
cases due to respiratory infections of the lower
respiratory tract. A total of four cases of PCP
occurred in patients receiving HAARTwho had more
than 18% CD4 (>200 cells  106/L) and in whom
prophylaxis had been discontinued, according to
guidelines.
Tobacco use
A total of 338 of the 521 HIV-infected men and
women reported current tobacco use. As shown in
Table 1, the overall rate of current smoking was 65%
for men (197/300) and 60% for women (131/221).
Nearly 24% of the men and 27% of the women
reported never smoking cigarettes. A small percen-
tage of the men (11%) and women (13%) had stopped
smoking. Overall, 93% of adults who smoked were
daily smokers (95% CI 89.8—95.7), and 6.8% (95% CI
4.3—10.2) were sometimes smokers (over three
times per week). Most tobacco users (95%) smoked
cigarettes, with a small percentage preferring
cigars (1.6%), pipes (2.5%) or chewing tobacco
(0.5%). Overall, current smokers reported smoking
an average of 15  13 cigarettes per day. Almost half
of the study group (40%) smoked more than one pack
of cigarettes per day. Most of the study participants
were long-term smokers 15  14 years; and 59% had
been smoking for more than ten years. Smokers
reported being diagnosed with HIV for a longer
time (8  6 years) than non-smokers (5.7  5.5;
p = 0.0001).
As shown in Table 1, there was no significant
difference in the mean age or in CDC/HIV classifica-
tion between smokers and non-smokers. The level of
education was similar in smokers (9.6  4 years) and
non-smokers (9  4.6 years), and neither income
nor education were significantly associated with
the prevalence or amount of smoking. There were
substantial differences in smoking rates among dif-
ferent racial/ethnic groups. Caucasian respondents
had the highest smoking rates (95%) followed byAfrican Americans (73%), Hispanics (62%) and Hai-
tians (21%).
Tobacco use and respiratory disease
A higher proportion of smokers (58%) were admitted
to the hospital for a pulmonary infection as com-
pared to non-smokers (37%, p = 0.0005). Univariate
analyses indicated that smokers were twice as likely
to be hospitalized with a respiratory infection than
any other disease (95% CI 1.33—2.83; p = 0.003).
Further analyses were performed to determine
whether this association was valid for each respira-
tory infection (i.e. community acquired pneumonia,
tuberculosis, NTM, PCP). Based on these analyses an
association was evident between smoking and PCP
pneumonia (r = 0.287, p = 0.008). It was also con-
firmed for CAP, which comprised a third (33%) of the
total respiratory admissions in smokers, but only 21%
of admissions in non-smokers ( p = 0.02). Current
tobacco smokers were nearly twice as likely as
non-smokers to be hospitalized with CAP (OR =
1.80, 95% CI 1.16—2.79, p = 0.005).
PCP was evident in significantly more smokers
(16%) than non-smokers (8%, p = 0.009). Most of the
PCP patients (90%), in fact, were smokers: 78%
smoked cigarettes and 22% smoked drugs. The esti-
mated crude odds ratio (OR) of the association
between tobacco use and being hospitalized with
PCP was 2.55 (95% CI 1.27—4.77; p = 0.004). No
association was observed, however, between cur-
rent tobacco use and mycobacterial disease.
Tobacco use, respiratory infection, and
immune status
When HIV status was more closely evaluated, first by
CD4 count and then by AIDS-defining symptoms,
differences were evident between the two groups.
Although mean CD4 cell counts were significantly
higher in smokers (137.7  108.6  106/L) com-
pared to non-smokers (100.4  125.7  106/L;
p = 0.001) non-smokers had a higher proportion of
subjects with CD4 counts above 200  106/L (25% vs.
21%, p = 0.3; immunological AIDS). More smokers
than non-smokers tended to have AIDS-defining
symptoms (PCP, repetitive CAP etc; p = 0.085),
while mean viral load levels were similar in smokers
and non-smokers. There was no difference in the
proportion of smokers vs. non-smokers receiving
HAART or non-HAART.
Figure 1 illustrates tobacco’s impact on respira-
tory infections as stratified by CDC stages. A CD4 cell
count less than 200 was also a significant predictor
of being hospitalized with PCP ( p = 0.009). Signifi-
cantly more smokers who were classified as stage C
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Figure 1 Tobacco’s impact on respiratory infections as
stratified by CD4 cell count. Among subjects with CD4 cell
counts <200  106/L, significantly more smokers (light
bars) than non-smokers (dark bar) had PCP (21% vs. 9%;
p = 0.001) and CAP (31.5% vs. 20.6%; p = 0.02). Similarly,
in subjects with CD4 counts between 200—500 < 200 
106/L, a higher proportion of smokers developed CAP (42%)
compared to non-smokers (21%; p = 0.04). PCP occurred
only in smokers in this group. Above CD4 counts 500 
106/L, only CAP occurred, mainly in smokers (78% vs.
22%; p = 0.05).
Table 2 Final analyses.
Wald Odds ratio Significance
p-value
Tuberculosis
Smoking 0.728 1.309 0.394
CD4 3.960 2.377 0.047
PCP
Smoking 14.159 3.500 0.000
CD4 11.899 6.458 0.001
Pneumonia
Smoking 12.586 2.278 0.000
CD4 0.206 1.118 0.650(CD4 cell counts<200  106/L) had PCP than stage C
non-smokers (21% vs. 9%; p = 0.001). The relative
hazard for current vs. non-smokers was higher in
subjects diagnosed with PCP (OR = 2.7, 95% CI 1.4—
5.3; p = 0.002). Significantly more stage C smokers
than non-smokers had CAP (31.5% vs. 20.6%;
p = 0.02). The rate of hospitalization for CAP at
stage C (AIDS) was approximately twice as great
in smokers than in non-smokers (95% CI 1.1—2.9;
p = 0.02).
Differences in respiratory infection patterns
were also noted in Stage B patients (CD4 counts
200—500  106/L). All PCP cases occurred in smo-
kers. Additionally, a higher proportion of stage B
smokers developed CAP (42%) as compared to non-
smokers (21%, p = 0.04). Of the 29 patients who had
more than 500  106/L CD4 cell counts, themajority
(n = 17) were hospitalized for non-respiratory
causes and 12 were admitted with respiratory ail-
ments. Of those hospitalized for respiratory infec-
tions 9/12 had CAP and 78% of the CAP cases (7/9)
occurred among smokers. The relative hazard of
developing CAP for current vs. non-smokers was
similar for subjects with baseline CD4 <200 and
200  106/L (OR = 2, p = 0.05). No significant dif-
ferences in the proportion of other respiratory
infections were observed between smokers and
non-smokers.
No differences in the risk of TB were evident
between smokers and non-smokers regardless of
CDC staging (C1 and C2).
The prevalence of respiratory infections was com-
paredbetween smokers andnon-smokersmatchedbyHAART administration. Among non-HAART treated
individuals, a significantly higher proportion of smo-
kers than non-smokers were hospitalized with both
PCP and CAP (p = 0.03). Significantly more of the
HAART-treated individuals who were classified as
smokers were hospitalized with CAP than non-smo-
kers (61% vs. 39%; Chi-square = 6.5; p = 0.01). A simi-
lar tendencywas observed in smokerswho developed
PCP relative to non-smokers (p = 0.07). During the
study period, ten tuberculosis and 14 NTM cases
occurred among patients receiving HAART.
Final analyses
The CATMOD procedure was used for the final ana-
lyses, adjusting for HAART and viral load. The final
model indicated that cigarette smoking was a sig-
nificant independent predictor of CAP and PCP.
Smokers were twice as likely to be hospitalized with
CAP, and 3.5 times more likely to be hospitalized
with PCP than the controls (see Table 2). Low total
CD4 cell counts were a significant risk factor for both
mycobacterial disease and PCP, but not CAP.
Analyses of tobacco use frequency (current num-
ber cigarettes/day) indicated a dose-dependent
relationship (3% risk/cigarette/day) as follows:
smokers of one pack per day were 1.8 times more
likely to develop CAP/PCP; the risk significantly
increased (OR = 3.35) for those consuming two packs
per day, and so forth.Discussion
This is the first case-control, cross-sectional study to
examine the impact of smoking on the cause of
respiratory hospitalizations, particularly PCP, among
consecutively admittedHIV-infected subjects, during
the HAART era. Using both CATMOD and dose-
response analyses, controlling for HAART, viral load
and CD4, the data revealed that cigarette smoking is
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of morbidity and mortality in HIV-infected adults:
PCP and CAP.
Results of this study, which demonstrate wide-
spread tobacco use in association with hospitaliza-
tion for lower tract respiratory disease, are
strengthened by the high diagnostic capabilities
and medical experience of one of the largest HIV
healthcare centers in the nation. Similar to findings
in non-HIV-infected individuals,14—17 these results
indicate significant differences in the overall total
number of hospitalizations between HIV-infected
smokers and non-smokers, resulting in excess costs
and healthcare burden among smokers.
Tobacco use, which was strikingly prominent in
both HIV-infected men and women, significantly
increased the risk of pulmonary infection, despite
the administration of antiretroviral therapy. This is
of particular concern as lower respiratory infections
are the main cause of hospitalization in both HIV-
infected men and women. Although cigarette smok-
ing is a well-established risk factor for the devel-
opment of bacterial pneumonia, the effects of
smoking in relationship to Pneumocystis carinii
pneumonia have not been thoroughly investigated.
In the Miami study population, PCP was prevalent
(12.4/100 patient/year) and was significantly asso-
ciated with tobacco use. Moreover, smoking and CD4
cell counts were the only independent predictors of
PCP hospitalization after controlling for viral load
and HAART in the regression analyses. These findings
confirm the authors’ earlier study1 and extend these
results to establish, for the first time, a dose-depen-
dent relationship between smoking and the risk of
developing PCP. The risk of developing PCP is
doubled as the number of packs of cigarettes per
day increases. In accordance with this proposal,
Singer and collaborators17 have shown that serum
angiotensin-converting enzyme (ACE) levels are sig-
nificantly elevated in PCP patients who smoke (55 
15 U/L) as compared to non-smokers (42  10 U/L,
p < 0.025), suggesting increased respiratory dis-
tress in smokers.17
In contrast to the present findings, two previous
investigations concluded that smoking was not sig-
nificantly associated with progression to PCP, AIDS,
or death.3,5 This disparity may be related to differ-
ences in study populations and designs. Whereas
the results of Burns et al.5 and Galai et al.3 were
based on either patient reports and/or AIDS report-
ing systems, the diagnoses here were based on
pathogen isolation and, for approximately one
third of the group, strict physician-determined
clinical criteria. Additionally, the Miami study
group included a very diverse multi-ethnic popula-
tion with a large number of women, along withheterosexuals, drug users and a small proportion of
homo/bisexuals, whereas Galai’s study3 was based
primarily on a cohort of homosexuals. Similarly,
Burns’s study5 primarily followed homosexual/
bisexuals, and some drug users, with a small pro-
portion of women.
Furthermore, as opposed to the small proportion
of heavy smokers (16% >1 pack/day) in Burns’s
study,5 35% of the Miami study population were
heavy smokers (>1 pack/day). Although the study
groups were very different, it should be noted that
both Galai et al.3 and Burns et al.5 reported an
association between smoking and oral candidiasis,
which has been related to an increased risk of
Pneumocystis carinii pneumonia.18
It is important to highlight that, while PCP cases
were associated with low CD4 cell counts, some
cases occurred in patients with CD4 counts more
than 200  106/L. This is in agreement with previous
studies in HIV-negative patients, showing pulmonary
colonization with PCP in patients with CD4+ lym-
phocyte counts below 400  106/L.19—21 Trimetho-
prim-sulfamethoxazole was the most commonly
prescribed medication for prophylaxis of PCP and
was given to 30% of the study population. Of inter-
est, a small number of PCP cases (n = 4) occurred in
HAART-treated patients with more than 18% CD4
cells who were not receiving prophylaxis. All were
smokers, underscoring the importance of determin-
ing risk factors before suspending therapy. Even
though the occurrence of PCP has been previously
described in HAART-treated patients, it needs to be
recognized that both non-adherence and/or antire-
troviral resistance could be contributing to the
results.
These findings are in accordance with previous
studies documenting an increased risk of commu-
nity-acquired pneumonias among smokers.5 This is
in sharp contrast to other reports that smoking may
not have a marked effect on CD4 cell counts or
clinical outcome.22,4 In the present investigation,
CAP was the chief cause of respiratory hospitaliza-
tions, supporting the findings of Paul and colleagues8
indicating that HAART treatment is least effective in
reducing the incidence of CAP. Furthermore, bac-
terial pneumonia has been shown to be more com-
mon in the present HAARTera than in the pre-HAART
era.7 This is not unexpected, considering that CAP is
mainly influenced by humoral system responses, and
therefore not as dependent on cellular responses.
Immune reconstitution achieved with HAART is not
always complete, further complicating the risk of
infection.23,24 The elevated risk for pulmonary dis-
ease observed in HIV-infected cigarette smokers
may be related to alterations in pulmonary struc-
tures and immunologic defenses. Smokers have
216 M.J. Miguez-Burbano et al.been found to have increased bacterial adherence in
the respiratory tract, decreased serum and salivary
IgA and IgG, and abnormal production of cytokines
with a TH1 to TH2 switch. The elevated risk of
developing respiratory infections in tobacco users
may also be attributed to increased oxidative stress
resulting from the relatively high concentration of
free radicals in cigarette smoke.25 The hazard of
developing CAP among HIV-infected smokers is simi-
lar to the risk previously described in the general
population.26 It is notable that most pneumonias in
non-immunocompromised hosts can be managed in
outpatient clinics. In this investigation, however,
the risk of hospitalization due to CAP was slightly
higher than the one reported by Farr for the general
population.12 The high risk of CAP infection among
HIV-infected individuals is of particular concern, as
bacterial pneumonia carries a mortality rate that
ranges from 2.6—27% in-hospital or four weeks after
discharge.16,27—29
It is recognized that the present data reflect only
HIV-infected subjects who were hospitalized at
Jackson Memorial Hospital and are based primarily
on patients with marked immunosuppression. More-
over, the extent of under-reporting or over-report-
ing cannot be determined, although the survey
questions demonstrate good reliability when com-
pared tomedical records. The current investigation,
nevertheless, is one of the first large studies to link
cigarette smoking to respiratory hospitalizations in
HIV-infected patients. Findings from this study
demonstrate a dramatically increased risk for devel-
oping pulmonary infections including PCP in HIV-
infected smokers in a dose-dependent manner, sug-
gesting that current guidelines regarding prophy-
laxis may need to be reviewed, especially for HIV-
infected smokers administered HAART. Of critical
importance is that HIV-infected persons who smoke
need to be informed of their increased risk for
developing respiratory infections. Smoking cessa-
tion programs should be encouraged and educa-
tional campaigns designed to specifically target
HIV-infected populations. Reduction in smoking pre-
valence among HIV-infected men and women could
result in substantial decreases in health-related
costs, lost productivity, and human suffering.Acknowledgements
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